hotspot -WSS

hotspot

author：entertainment 2025-09-29 21:26:52 - browse：7

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Chronically ill young patients struggle to find fertility info

WSS

A single drug, study failures leave Anavex with nothing but cash

Why psychiatrists like me stop taking insurance

Structure Therapeutics oral GLP

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Ahead of JPM, here's who's profiting most in health care

A single drug, study failures leave Anavex with nothing but cash

explore

hotspot

entertainment

Sports medicine is finally prioritizing gender equality

3 medical device trends to watch in 2024

Alkermes shareholders re

Stopping antidepressants leads to symptoms for 1 in 6 patients

23andMe had bad news about my health. I wish a person had delivered it

Congress needs to close a vaccine

Apple is now the first public company to be valued at $3 trillion

FDA approves Moderna’s RSV vaccine, its second licensed product

After affirmative action ruling, medical educators look to 'holistic review'

A single drug, study failures leave Anavex with nothing but cash

leisure time

ASCO Daily Recap: CAR

Morgan Health, with ambitious aims, wants you to know it’s still here

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

BD to buy Edwards patient monitoring unit for $4.2 billion

STAT wants to know your pick for a great summer read or listen

The most pressing bird flu mysteries scientists want answered

hotspot

hotspot

explore

hotspot